KBC Group
RCUS icon

KBC Group’s Arcus Biosciences RCUS Stock Holding History

KBC Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72K Hold
2,334
– – ﹤0.01% 1577
2026
Q1 		$50K Buy
+2,334
New +$50.4K ﹤0.01% 1654
2024
Q2 		– Sell
-1,952
Closed -$37K – 1904
2024
Q1 		$37K Hold
1,952
– – ﹤0.01% 1698
2023
Q4 		$37K Hold
1,952
– – ﹤0.01% 1712
2023
Q3 		$35K Sell
1,952
-2,076
-52% -$41.7K ﹤0.01% 1715
2023
Q2 		$82K Hold
4,028
– – ﹤0.01% 1243
2023
Q1 		$73K Hold
4,028
– – ﹤0.01% 1297
2022
Q4 		$83K Hold
4,028
– – ﹤0.01% 1269
2022
Q3 		$105K Hold
4,028
– – ﹤0.01% 1166
2022
Q2 		$102K Buy
+4,028
New +$98.6K ﹤0.01% 1214

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

KBC Group's RCUS Position: Q2 2026 in Review

KBC Group held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 2,334 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1577.

KBC Group first reported a position in RCUS in Q2 2022 and has held it in 10 quarters since. The position peaked at $105K in Q3 2022. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • KBC Group held 2,334 shares of Arcus Biosciences worth $72K as of Q2 2026.
  • KBC Group left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1577 holding.
  • KBC Group first reported a position in Arcus Biosciences in Q2 2022 and has held it in 10 quarters since.
  • KBC Group's Arcus Biosciences position peaked at $105K in Q3 2022.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.